Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Active not recruiting 2Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Hepatocellular 129Carcinoma, Renal Cell 36Parkinson Disease 4, Autosomal Dominant Lewy Body 31Neoplasms 27Cholangiocarcinoma 23Endometrial Neoplasms 19Liver Neoplasms 16Melanoma 15Thyroid Neoplasms 13Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Biliary Tract Neoplasms 12Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 8Recurrence 8Ovarian Neoplasms 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 5Thyroid Carcinoma, Anaplastic 5Small Cell Lung Carcinoma 5Neuroendocrine Tumors 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma 4Thyroid Cancer, Papillary 3Solid Tumors 3

Interventions

Etoposide 153Carboplatin 140Cisplatin 103Topotecan 74durvalumab 48atezolizumab 45Irinotecan 44pembrolizumab 38Paclitaxel 34Nivolumab 33Radiotherapy 29anlotinib 23PM 01183 21Gemcitabine 21Drug Therapy 20apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Bevacizumab 13amrubicin 11Magnetic Resonance Spectroscopy 11Cyclophosphamide 11rovalpituzumab tesirine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Small Cell Lung Carcinoma × lenvatinib × Clear all
NCT04938817 2026-05-27

KEYNOTE-B98

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
110 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04924101 2025-07-23

KEYNOTE-B99

Merck Sharp & Dohme LLC

Phase 2 Completed
126 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Salubris Biotherapeutics Inc

Phase 1/2 Active not recruiting
263 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04951947 2024-09-19

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Hunan Province Tumor Hospital

Phase 2 Recruiting
30 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT05296603 2024-01-10

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

Hunan Province Tumor Hospital

Phase 2 Unknown
83 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡